Latest filing published 25 Nov 2025 for NEKTAR THERAPEUTICS, €30k.
Filing timeline
BuySaleInsider track record
Mark Andrew Wilson: trading record in brief
Mark Andrew Wilson (senior executive) discloses dealings in Nektar Therapeutics to SEC (Form 4). Between 18 May 2020 and 25 November 2025, the trades on record add up to 33 filings.
Every open-market trade on record is a sale: 26 sales worth €593k. Outside the open market, there are 6 share grants and 1 option exercise. In 2025 alone, the filings show no purchases and 4 sales.
Most recently, on 25 November 2025, the filings show an open-market sale worth €30k in Nektar Therapeutics. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Mark Andrew Wilson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 630 shares@ US$54.284.7% of flowCommon StockSEC:0001193125-25-297852:1
- 1,903 shares0Common StockSEC:0001193125-25-297852:0
- 676 shares@ US$26.59100.0% of flowCommon StockSEC:0000950170-25-110774:0
- 9,996 shares@ US$0.672.5% of flowCommon StockSEC:0000950170-25-075977:0
- 11,040 shares@ US$1.014.5% of flowCommon StockSEC:0000950170-25-025040:0
- 16,560 shares@ US$0.892.2% of flowCommon StockSEC:0000950170-24-140591:1
- 33,402 shares@ US$0.9012.1% of flowCommon StockSEC:0000950170-24-140591:0
- 165,938 shares0Common StockSEC:0000950170-24-137544:0
- 6,407 shares@ US$1.012.6% of flowCommon StockSEC:0000950170-24-129462:0
- 5,651 shares@ US$1.282.7% of flowCommon StockSEC:0000950170-24-099353:0
- 6,260 shares@ US$1.754.2% of flowCommon StockSEC:0000950170-24-062644:0
- 7,606 shares@ US$0.682.0% of flowCommon StockSEC:0000950170-24-019044:0
- 7,179 shares@ US$0.491.4% of flowCommon StockSEC:0001209191-23-056183:0
- 7,221 shares@ US$0.782.2% of flowCommon StockSEC:0001209191-23-046461:0
- 7,543 shares@ US$0.722.1% of flowCommon StockSEC:0001209191-23-030447:0
- 8,275 shares@ US$3.009.8% of flowCommon StockSEC:0001209191-23-010954:0
- 8,690 shares@ US$3.5712.6% of flowCommon StockSEC:0001209191-22-057967:0
- 3,189 shares@ US$4.762.4% of flowCommon StockSEC:0001209191-22-046488:1
- 165,938 shares0Common StockSEC:0001209191-22-046488:0
- 3,136 shares@ US$3.955.0% of flowCommon StockSEC:0001209191-22-029904:0
- 3,661 shares@ US$10.9514.8% of flowCommon StockSEC:0001209191-22-011441:0
- 37,800 shares0Common StockSEC:0001209191-21-070695:0
- 6,564 shares@ US$13.1613.2% of flowCommon StockSEC:0001209191-21-065225:1
- 20,100 shares0Common StockSEC:0001209191-21-065225:0
- 1,910 shares@ US$13.839.4% of flowCommon StockSEC:0001209191-21-052393:0
25 of 33 declarations
